Kisqali Access Registry for Metastatic Breast Cancer in Australia

Not Applicable

Recruiting

• Conditions: Breast Cancer; Cancer - Breast

• Registration Number: ACTRN12619001138178
• Lead Sponsor: The Walter and Eliza Hall Institute of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-08-15
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 250

Inclusion Criteria

Patients who meet the following inclusion criteria are eligible for the study:
• Age is 18 or over
• Patients with metastatic or advanced HR positive, HER2 –ve breast cancer who have received combination treatment with ribociclib and an aromatase inhibitor as part of the Novartis ribociclib MAP/SPARK program between the period of 1 May 2017 to 30 June 2018

Exclusion Criteria

Patients who have opted out of data collection will be excluded from the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Real world clinical and tumour characteristics, and treatment description of patients with HR+ HER2–ve MBC in Australia who have received ribociclib in combination with an aromatase inhibitor as part of the ribociclib MAP and/or SPARK access program. Assessed by entry into medical records.[1) At enrolment/baseline<br>2) 12 months post enrolment]